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Abstract
Objective
The aim of this study was to expand the spectrum of epilepsy syndromes related to STX1B, encoding the
presynaptic protein syntaxin-1B, and establish genotype-phenotype correlations by identifying further disease-
related variants.
Methods
We used next-generation sequencing in the framework of research projects and diagnostic testing. Clinical data
and EEGs were reviewed, including already published cases. To estimate the pathogenicity of the variants, we used
established and newly developed in silico prediction tools.
Results
We describe 17 new variants in STX1B, which are distributed across the whole gene. We discerned 4 different
phenotypic groups across the newly identified and previously published patients (49 patients in 23 families): (1) 6
sporadic patients or families (31 affected individuals) with febrile and afebrile seizures with a benign course, generally
good drug response, normal development, and without permanent neurologic deficits; (2) 2 patients with genetic
generalized epilepsy without febrile seizures and cognitive deficits; (3) 13 patients or families with intractable seizures,
developmental regression after seizure onset and additional neuropsychiatric symptoms; (4) 2 patients with focal
epilepsy. More often, we found loss-of-function mutations in benign syndromes, whereas missense variants in the
SNARE motif of syntaxin-1B were associated with more severe phenotypes.
Conclusion
These data expand the genetic and phenotypic spectrumof STX1B-related epilepsies to a diverse range of epilepsies that
span the International League Against Epilepsy classification. Variants in STX1B are protean and contribute to many
different epilepsy phenotypes, similar to SCN1A, the most important gene associated with fever-associated epilepsies.
From theUniversity of Tu¨bingen (S.Wolking, J.M., Y.G.W.,H.L., J.S.),DepartmentofNeurologyandEpileptology,Hertie Institute forClinicalBrainResearch, Tu¨bingen,Germany; LuxembourgCentre forSystems
Biomedicine (P.M.), University of Luxembourg, Esch-sur-Alzette; Pediatric Neurology and Neurogenetics Unit and Laboratories (D.M., R.G., C.M.), Children’s Hospital AnnaMeyer, University of Florence, Italy;
Danish Epilepsy Centre (R.S.M.), Dianalund; Institute for Regional Health Services (R.S.M.), University of Southern Denmark, Odense; Department of Clinical and Experimental Epilepsy (S.B.), UCL Institute of
Neurology and Epilepsy Society, UK, London; Division of Neurology (K.L.H., I.H.), Children’s Hospital of Philadelphia, PA; Department of Pediatric Neurology (C.D.A.), Centre de Compe´tencesMaladies Rares,
CHUBesançon;ServicedeGe´ne´tique (N.C.),HospicesCivilsdesLyon,Bron;GENDEVTeam(N.C.),NeurosciencesResearchCenterofLyon,Bron,France;NeuropediatricClinicandClinic forNeurorehabilitation
(K.S.), Epilepsy Center for Children and Adolescents, Schoen Klinik Vogtareuth, Germany; Beaumont Hospital (P.W.-W.), Dublin, Ireland; Department of Pediatrics, Division of Medical Genetics, Institute of
Human Genetics (B.A.M.), Departments of Neurology and Pediatrics (A.N.), and Departments of Neurology and Pediatrics, and Institute of Human Genetics (M.R.C.), University of California, San Francisco;
Department ofNeurology (W.V.P.), UniversityHospitals Leuven, Belgium;Department of Pediatrics (L.L.S.), HvidovreHospital, Denmark; King’sCollegeHospital (S.O., E.H., S.G., D.K.P.), London; Evelina London
Children’sHospital (S.O., E.H., S.G.), London, UK; Section of Genetics (K.B.,M.S.S.), Department of Pediatrics, University of Colorado andChildren’sHospital Colorado, Aurora; CliniqueBernoiseMontana (T.D.),
Crans-Montana, Switzerland;Department ofNeuropediatrics (H.M.), UniversityMedical Center Schleswig-Holstein, Christian-AlbrechtsUniversity, Kiel, Germany;National Institute forHealth ResearchOxford
Biomedical ResearchCentre,WellcomeCentre forHumanGenetics (A.T.P., S.J.L.K., J.C.T.) andDepartment ofOncology (D.V.V.), University ofOxford, UK; Epilepsy Center (M.P.C.), Health SciencesDepartment,
SanPaoloHospital, University ofMilan; ChildNeuropsychiatry (F.D.), Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Italy; Departments ofNeurology andClinical
Genomics (R.H.G.) andHealthSciencesResearchandClinicalGenomics (E.W.K., C.K.),MayoClinic,Rochester,MN;AmbryGenetics (Z.P.), AlisoViejo,CA;DepartmentofClinicalNeuroscience (S.T.), King’sCollege
London; New Medicines (M.A., D.M.), UCB Pharma, Slough, UK; Neuropediatric Clinic and Clinic for Neurorehabilitation (G.J.K.), Epilepsy Center for Children and Adolescents, Schoen Klinik Vogtareuth,
Germany; Research Institute for Rehabilitation, Transition and Palliation (G.J.K.), PMU Salzburg, Austria; Department of Neurology (D.H.L.), University of California, San Francisco; Neurogenetics Group (S.
Weckhuysen), Center forMolecularNeurology, VIB, Antwerp; Laboratory ofNeurogenetics (S.Weckhuysen), Institute Born-Bunge, University of Antwerp; Department ofNeurology (S.Weckhuysen), Antwerp
UniversityHospital, Antwerp, Belgium;Department of Basic&Clinical Neuroscience, Institute of Psychiatry, Psychology&Neuroscience (D.K.P.),MRCCentre forNeurodevelopmentalDisorders (D.K.P.), King’s
College London,UK; Evelina LondonChildren’sHospital (D.K.P.), London, UK;Department ofNeuropediatrics (I.H.), UniversityMedical Center Schleswig-Holstein, Christian-AlbrechtsUniversity, Kiel, Germany;
Institute of Neuroscience (R.H.T.), Henry Wellcome Building, Newcastle University; Neurology Research Group (M.I.R.), Institute of Life Science, Swansea University Medical School, Swansea, UK; Service de
Ge´ne´tique (G.L.), Hospices Civils des Lyon, Bron; GENDEV Team (G.L.), Neurosciences Research Center of Lyon, Bron, France; NIHR University College London Hospitals Biomedical Research Centre (S.M.S.),
UCL Institute of Neurology, London, UK; Cologne Center for Genomics (D.L.), University of Cologne, Germany; Stanley Center for Psychiatric Research (D.L.) and Program inMedical and Population Genetics
(D.L.), Broad Institute of MIT and Harvard, Cambridge; Psychiatric and Neurodevelopmental Genetics Unit (D.L.), Massachusetts General Hospital and Harvard Medical School, Boston.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was funded by Wellcome Trust.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
 Published Ahead of Print on February 8, 2019 as 10.1212/WNL.0000000000007089
Genetic generalized epilepsies (GGEs) and genetic epilepsies
with febrile seizures (FS) plus (GEFS+) are genetically and
phenotypically heterogeneous epileptic disorders. GGEs share
common clinical hallmarks such as seizure types, generalized
epileptic discharges on EEG, and typical onset between child-
hood and adolescence. Most GGE cases have a polygenic in-
heritance, but a few monogenic causes have been identified,
such as GABRA1,1 SLC2A1,2 CACNA1H,3 as well as micro-
deletions, such as 15q13.3.4 GEFS+ is a familial epilepsy syn-
drome characterized by focal or generalized febrile and afebrile
seizures, and focal or generalized epileptiform discharges on
EEG. The clinical presentation may differ considerably among
affected individuals within the same family.5,6 Privatemutations
have been identified in genes encoding subunits of voltage-
gated Na+ channels (SCN1A, SCN1B)7,8 and the γ-amino-
butyric acid type A receptor (GABRG2, GABRD).9,10 Most of
the genes that are associated with GGE and GEFS+ are also
implicated in developmental and epileptic encephalopathies
(DEEs), which are characterized by seizure onset in the first
years of life, often pharmacoresistant seizures, cognitive re-
gression, and neurologic deficits. For certain genes, such as
SCN1A, a clear genotype-phenotype correlation is described: in
GEFS+, a greater proportion of missense variants is found,
whereas in Dravet syndrome, nonsense mutations or large
deletions are more common.11
Recently, we reported variants in the STX1B gene as a cause of
fever-associated epilepsies of variable severity.12 Two large
families showed a rather benign course of GEFS+ syndrome,
whereas 4 individuals had a more severe DEE phenotype. An
additional 18-year-old patient exhibiting epilepsy with
myoclonic-atonic seizures and moderate to severe intellectual
disability was reported recently.13
STX1B encodes syntaxin-1B, a presynaptic protein that is part
of the SNARE complex mediating the process of calcium-
dependent synaptic vesicle release.14
We aimed to describe additional variants in STX1B, charac-
terize the related clinical and EEG phenotypic spectrum, and
establish genotype-phenotype correlations.
Methods
Clinical data
We identified 49 individuals harboring heterozygous variants
in STX1B (NM_052874.3). The cases were pooled from
14 different centers identified through research studies and
clinical diagnostic testing. The cohort consists of 7 families
with 2 to 17 affected individuals and 16 sporadic patients. Of
these, we previously reported 2 large families and 4 sporadic
patients.12,15,16 We systematically collected clinical in-
formation such as age at onset, seizure type, neurologic and
cognitive deficits, neuroimaging outcome, and antiepileptic
drug (AED) treatment through a standardized questionnaire.
We reviewed original EEG recordings (S. Wolking., H.L., T.D.,
C.M., P.W.-W., D.M.) for all but 3 patients (F3, F15, F18).
EEGs for F1 and F2were described in previous publications.15,16
Standard protocol approvals, registrations,
and patient consents
Written informed consent to participate in this study was
obtained from all patients or caregivers.
Genetics
We used different next-generation sequencing datasets from
multicenter research projects or diagnostic testing services to
identify the reported STX1B variants. The methods and the
centers are available fromDryad (doi:10.5061/dryad.cf0hj73)
and in our previous report.12 All patients are of European
descent.
To evaluate the effect of the missense variants, we used well-
established in silico prediction tools: SIFT (sorting tolerant
from intolerant),17 PolyPhen-2 (polymorphism phenotyping
v2),18 and MutationTaster.19 We compared patient STX1B
missense variants to variants identified in almost 150,000
control individuals stored in the Genome Aggregation Data-
base (gnomAD, gnomad.broadinstitute.org/).20 Mutation
density was calculated by counting the number of variant
positions in gnomAD divided by the window length within
a window of 10 nucleotides using a sliding window approach
over the coding sequence of the STX1B transcript NM_
052874.3. We determined paralog conservation as described
by Lal et al.21 In short, we aligned the canonical protein
sequences of the 7 paralog genes of the Ensembl SYNTAXIN
protein family, STX2, STX1A, STX11, STX1B, STX19, STX3,
and STX4 and scored the conservation at each alignment
position using JalView.22 Then we determined the mean and
the standard deviation paralog conservation for each single
protein of the protein family and a z score (para_zscore)
calculated for each residue position. We defined paralog
conservation as para_zscore >0.
Data availability
Data not published in this article will be shared as anonymized
data by request from any qualified investigator.
Glossary
DEE = developmental and epileptic encephalopathy; FS = febrile seizures;GEFS+ = genetic epilepsies with febrile seizures plus;
GGE = genetic generalized epilepsy; gnomAD = Genome Aggregation Database; GTCS = generalized tonic-clonic seizure;
JME = juvenile myoclonic epilepsy; PolyPhen-2 = polymorphism phenotyping v2; SIFT = sorting tolerant from intolerant;
SNARE = SNAP (soluble NSF attachment protein) receptor.
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Results
Phenotypic descriptions
Reviewing the clinical characteristics of all patients, we could
distinguish 4 different phenotypic groups (numbering of the
families was defined as follows: F1–F6 as in our previous
study,12 F7–F23 new families sorted by phenotype). (1)
Three families and 3 sporadic patients with FS, with or
without additional generalized and more rarely focal afebrile
seizures, with a relatively benign course, generally good drug
response, normal development, and mild or no neuropsy-
chiatric symptoms, corresponding to GEFS+ (F1, 2, 7–10).
(2) Two unrelated patients with generalized myoclonic and
absence seizures, without FS, and without major cognitive
deficits, corresponding to juvenile myoclonic epilepsy (JME),
a common subtype of GGE (F11, 12). (3) Thirteen unrelated
patients with intractable seizures, occurrence of de-
velopmental stagnation or regression after seizure onset, and
additional neuropsychiatric deficits compatible with DEE
(F3–6, F13–21). (4) Two patients with some form of focal
epilepsy (F22, 23). The main clinical characteristics of all
families and sporadic patients are summarized in table 1.More
detailed clinical data are available from Dryad, doi.org/10.
5061/dryad.cf0hj73.
Group 1: GEFS+ (31 patients in families F1, F2, F7–10)
FS were present in the majority of patients. The first seizure
started between 10 months and 5 years (median 20 months).
There was a large variety of afebrile seizure types, including
generalized tonic-clonic seizures (GTCS) (n = 13), focal
impaired awareness seizures (n = 3), atonic seizures (n = 8),
tonic seizures (n = 4), and absence seizures (n = 5). Nine
patients had infrequent seizures until adulthood that did not
require treatment. For most cases, cognition was intact and
neurologic deficits were not frequent in this cohort (table 1).
Asymptomatic variant carriers were identified in 2 families (4
in F1, 3 in F2), which is of importance for genetic testing and
counseling in mild cases. Moreover, in F1, 4 phenocopies
were identified (2 patients with a GGE phenotype not
matching GEFS+, 1 individual with a single FS, and 1 patient
with falls and head nodding in early childhood that were later
interpreted as nonepileptic15).The treatment outcome in this
group was overall positive. More than 50% of patients were
seizure-free without medication (17); the remainder were
seizure-free with AED treatment (11). Only patient F7 had
ongoing seizures with valproic acid. EEGs showed focal and
generalized epileptiform discharges. Available ictal recordings
in F8.1 showed focal onset seizure.
Group 2: GGE (2 patients, F11, F12)
The first seizures for patient F11 were at age 18 years (gen-
eralized myoclonic seizures) followed by GTCS at 20 years,
and absences at 21 years. GTCS occurred in clusters of 3 or 4
seizures every 3 months. On neuropsychological examination,
the patient showed slight executive dysfunction; however, IQ
and memory functions were normal. F12 had his first seizures
at 11 years, featuring both afebrile myoclonic seizures and
GTCS. AWechsler Adult Intelligence test at 19 years revealed
an IQ of 85 ± 3. On examination, neither patient showed
deficits. Treatment was difficult, requiring multiple AED trials
in both patients (table 1).
For F11, the first EEG at age 21 showed an unusual pattern of
frequent bursts of generalized slow waves associated with
myoclonic jerks of both shoulders. Later, typical generalized
bursts of spikes and sharp waves were documented under
photic stimulation (he was the only photosensitive patient in
the whole cohort, as far as this was examined). For F12, the
first available EEG was performed at age 19 and showed oc-
casional brief bilateral epileptic discharges. A video-EEG at
age 24 demonstrated 4-Hz generalized spike-wave activity.
Video-EEGmonitoring at age 31 showed no epileptic activity.
Group 3: DEE (15 patients, F3–6, F13–21)
We retrieved detailed phenotypes for 12 of 15 patients. Epi-
lepsy onset was between 0 months and 3.5 years (median 15
months). Six patients (F5, F14, F16, F17, F20) had FS with
onset between 13 months and 2 years. F14 had only a single
FS after vaccination. Afebrile seizures comprised GTCS (n =
9), myoclonic (n = 10), atonic (n = 8), tonic seizures (n = 3),
atypical absences (n = 3), infantile spasms (n = 1), and hy-
perkinetic focal seizures (n = 1).
Except for F6, initial development was normal in all patients,
with severe global developmental delay or even regression
coinciding with seizure onset. In F19 and F21, global de-
velopmental delay and seizures were present since birth.
Neurologic examination showed anomalies in most patients
with ataxia being the most frequent finding.
Seizures were pharmacoresistant in all patients except F18,
undergoing on average 9 AED trials. Only F5 and F21 ach-
ieved seizure freedom with ongoing treatment. Of note, F4
responded with a significant seizure reduction to the com-
bined therapy of lamotrigine and valproic acid after several
unsuccessful AED trials. After the administration of bromide,
F14 showed a significant reduction in seizure frequency.
EEGs were available for review in 11 of 15 patients. Inter-
ictally, the EEGs in all cases showed multifocal epileptic dis-
charges that were predominantly located in the frontal or
temporal region. In addition, we detected generalized dis-
charges in 10 of 11 patients presenting as generalized spike-
wave or polyspike-wave discharges. In 4 of 11 patients, EEGs
showed frequent bursts of generalized rhythmic activity last-
ing several seconds. Ictal EEG recordings were available in 7
of 11 patients. In 4 patients, typical tonic seizures with gen-
eralized beta activity with increasing amplitude and decreasing
frequency were recorded. EEG curves are available from
Dryad (additional figures), doi:10.5061/dryad.cf0hj73.
Group 4: Focal epilepsy (2 patients, F22, F23)
F22 had right temporal lobe epilepsy, with a single FS reported at
6 years. Afebrile impaired awareness seizures with automatisms
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Table 1 Condensed phenotypes of patients and families F1–F23
ID No. Variant
FS; AaO
(y)
Nonfebrile
seizures;
AaO (y),
seizure
type
Intellectual
disability
Neurologic
examination EEG
Outcome
(current
AEDs)
Genetic
epilepsy with
febrile seizures
plus
F1 17 c.166C>T; p.Q56* 1.5-7; 3
patients
w/o FS
1.7-6; 2
exceptions
with onset
in
adulthood;
GTCS (6), AS
(4), Abs (4),
TS (2)
Asperger
syndrome (2)
Normal 3-4/s GSW (5),
FSW (1)
All Sf,
most w/o
treatment
F2 8 c.133_
134insGGATGTGCATTG;
p.K45delinsRCMIE and
c.135_136AC>GA;
p.L46M
1.2-3; 2
patients
w/o FS
1.2-1.7;
GTCS (5),
FIAS (3), AS
(3)
Dyslexia (1),
dyscalculia (1),
learning
disability (1)
Macrocephaly
(1)
FSW (7), GSW (7) All Sf, 4
w/o
treatment
F7 1 c.23_26dupTGCG;
p.S10Afs*7; de novo
0.8/NA,
GTCS
1.3; GTCS Normal Mild
hypotonia
NA Os (VPA)
F8 3 c.852dup; p.T285Dfs*75 0.9-1.4 5 (1); GTCS,
TS
Learning
disability (1)
Normal FSW (1) All Sf, 2
under
treatment
(VPA, PB)
F9 1 c.733C>T; p.R245* 2; FIAS,
GTCS
3; FIAS Normal Normal FSW Sf (OXC)
F10 1 c.420C>G; p.Y140* 2; AS,
GTCS
NA Mild Mild
dysmorphic
features
FSW Sf (VPA,
CLB)
Genetic
generalized
epilepsy
F11 1 c.628G>A; p.E210K NA 18; GTCS,
Myo, Abs
Impaired
executive
functions
Normal GSW,
photosensitive
Os (LEV,
CLB)
F12 1 c.277A>T; p.K93* NA 11; GTCS,
Myo
Normal Normal GSW Sf (VPA,
LEV, TPM)
Developmental
and epileptic
encephalopathy
F3 1 c.140C>A; p.S47*, de
novo
uk uk uk uk uk uk
F4 1 c.657T>A; p.V216E NA 3.5; GTCS,
TS, Myo, Abs
Moderate
cognitive
impairment
Ataxia,
dysarthria,
macrocephaly
FSW, GSW Os (VPA,
LTG)
F5 1 c.678G>C, p.G226R, de
novo
1.1 1.7; GTCS,
Myo, Abs,
AS, TS
Developmental
regression
Ataxia 3.5/s GSW, FSW Sf (LEV,
STP, VPA)
F6 1 arr[hg19] 16p11.2
(30,332,532-31,104,012)
x1; de novo
NA 1.1; Myo, AS,
GTCS
Developmental
regression
Mild
dysmorphic
features
FSW Os (CLB,
STP)
F13 2 c.563dupA; p.N189Afs*5 NA 0.8-1.3; Myo
(2), atyp Abs
(2), GTCS (2),
TS (2)
Developmental
regression (1)
Ataxia (1),
dystonia (1)
FSW (2), GSW (2) Os (PHT,
VPA, CBZ,
VGB)
Continued
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occurred at the same age. Sometimes she would describe an aura
with a rushing sensation in her head or blurred vision. Occa-
sionally, secondary generalization would occur. Interictal EEGs
showed right temporal epileptiform discharges. Ictal recording
of one seizure depicted a seizure onset over the entire right
hemisphere, with subsequent evolution most prominent over
the right temporal region. Neuropsychological testing and
neurologic examination were unremarkable. Repeated
MRIs showed nonspecific white matter lesions. An [18F]-
fluorodeoxyglucose–PET at age 28 revealed hypometabolism
in the right temporal lobe. Seizures were pharmacoresistant to
oxcarbazepine, lacosamide, and zonisamide.
In F23, weekly seizures started in teenage years with staring
episodes accompanied by subtle twitching of the right arm. In
addition, GTCS started at 24 years. Seizures were controlled with
lamotrigine. At 45 years, the patient developed stroke-like epi-
sodes featuring left-sided hemicrania, dilatation of the right pupil,
hemihypesthesia, and mild hemiparesis. The episodes lasted be-
tween 30 and 120 minutes and occurred about once a week. An
MRI at age 46 years showed no abnormalities. Previous EEGs
showed left temporal epileptiform discharges. However, themost
recent EEGs were normal. A video-EEG recorded during one of
the stroke-like episodes was without EEG correlate. Of note, in
the patient’s fifth decade of life, several autoimmune diseases were
diagnosed: type 1 diabetes mellitus, celiac disease, and hypo-
gammaglobulinemia. Treatment with IV immunoglobulins led to
a decrease in the frequency of the stroke-like episodes.
Molecular genetics
Of the 17 newly identified variants in STX1B, 8 are missense
(p.Val88Phe, p.Cys144Phe, p.Glu210Lys, p.Leu221Pro,
p.Ala246Pro, p.Ser258Gln, p.Arg261Gln, p.Ile282Thr),
5 frameshift (p.Ser10Alafs*7, p.Gln52Argfs*2, p.Glu128-
Glyfs*2, p.Asn189Alafs*5, p.Thr285Aspfs*75), and 3 stop
gain variants (p.Lys93*, p.Tyr140*, p.Arg245*). One patient
Table 1 Condensed phenotypes of patients and families F1–F23 (continued)
ID No. Variant
FS; AaO
(y)
Nonfebrile
seizures;
AaO (y),
seizure
type
Intellectual
disability
Neurologic
examination EEG
Outcome
(current
AEDs)
F14 1 c.845T>C; p.I282T; de
novo
1.3 2; Abs, Myo,
AS, TS
Developmental
regression
Ataxia,
aphasia
GPSW, GSW Os (VPA,
BR, ESM)
F15 1 c.773G>A; p.S258N uk uk uk uk uk uk
F16 1 c.662T>C; p.L221P 2 3; GTCS,
Abs, Myo,
AS, CPS
Developmental
stagnation
Mild ataxia GPSW, GPS Os (VPA,
LTG, LEV,
CLB)
F17 1 c.155delA; p.Q52Rfs*2;
de novo
1.3 4; GTCS,
Myo, Abs, AS
Developmental
regression
Dysarthria,
ataxia
GSW Os (LEV,
VPA)
F18 1 c.431G>T; p.C144F; de
novo
NA 0.8/16; Abs Developmental
stagnation
Ataxia,
tremor,
dysarthria
uk Sf (NA)
F19 1 c.736 G>C; p.A246P; de
novo
NA Since birth;
IS
Severely
impaired
Severe motor
and speech
impairment
Hypsarrhythmia Os (CBD)
F20 2 c.(?_242)_(*3565_?)del 2 (2) 2; AS (1), Abs
(1), Myo (1),
GTCS
Intellectual
impairment
Ataxia GPSW, GSW Os (VPA)
F21 1 c.383del; p.Q128Gfs*2 NA 0.2/Myo,
apnea and
cyanosis
Developmental
stagnation
Hypotonia GPSW Sf (CLB)
Focal epilepsy
F22 1 c.782G>A; p.R261Q 6 6; GTCS,
FIAS
Normal Normal FSW (right
temporal)
Os (OXC,
LCM, ZNS)
F23 1 c.262G>T; p.V88F NA 12; GTCS,
FIAS
Normal Normal FSW (left
temporal)
Sf (LTG)
Abbreviations: AaO = age at onset; Abs = absence seizure; AED = antiepileptic drug; AS = atonic seizure; atyp = atypical; BR = bromide; CBD = cannabidiol;
CBZ = carbamazepine; CLB= clobazam; CPS = complex partial seizure; ESM= ethosuximide; FIAS = focal impaired awareness seizure; FS = febrile seizures; FSW
= focal sharp waves; GPS = generalized polyspikes; GPSW = generalized polyspikes and sharpwaves; GSW = generalized sharp waves; GTCS = generalized
tonic-clonic seizure; IS = infantile spasms; LCM = lacosamide; LEV = levetiracetam; LTG = lamotrigine; Myo = generalized myoclonic seizure; NA = not
applicable; Os = ongoing seizures; OXC = oxcarbazepine; PB = phenobarbitone; PHT = phenytoin; Sf = seizure free; STP = stiripentol; TPM = topiramate; TS =
tonic seizure; uk = unknown; VGB = vigabatrin; VPA = valproic acid; w/o = without; ZNS = zonisamide.
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had a deletion of the entire gene (F20). Syntaxin-1B con-
sists of an N-terminal helical domain, containing the HA,
HB, and HC domains, the SNARE motif, and the C-terminal
transmembrane domain (figure 1A). When in close proximity
with SNAP-25 and synaptobrevin, syntaxin-1B forms the
SNARE complex that catalyzes membrane fusion in Ca2+-
triggered exocytosis. Syntaxin-1B can adopt 2 conformations:
open and closed. Both conformations are important for exo-
cytosis: the open conformation is necessary for the formation
of the SNARE complex, whereas the closed conformation
initiates the synaptic vesicle fusion reaction.23,24 Figure 1A
shows the new variants combined with those previously
reported in a schematic view of the syntaxin-1B protein. In
comparison to the location of loss-of-function variants, mis-
sense variants were more frequent in the second part of the
gene containing (1) the SNARE motif conveying interaction
with the other 2 components of the SNARE complex and (2)
the transmembrane domain, which is responsible for anchoring
syntaxin-1B into the cell membrane. None of these variants was
reported so far in the gnomAD database, currently the largest
collection of exomes and genomes publicly available.20 In
general, STX1B is intolerant to missense variants (missense z
score >3.63) and haploinsufficiency (pLI score of 0.94) in the
Exome Aggregation Consortium browser.20 Evaluation by
different in silico prediction tools (SIFT,17 PolyPhen-2,18
MutationTaster19) showed a damaging effect for 6 of 8 variants
in 3 of 3 prediction tools (table 2). We calculated the muta-
tional density of missense variants in the general population
from the Exome Aggregation Consortium using a sliding
window approach and could show that the variants are located
in regions of different mutational density (figure 2B). We also
calculated a paralog conservation score distribution for STX1B
(para_zscore)21 and highlighted the patient variants (figure
2C). This score gives the degree of conservation among paralog
Figure 1 STX1B gene with variants and pedigrees of newly identified variants
(A) Putative domain structure of syntaxin-1B derived from that for syntaxin-1A,24 as the isoforms share 83.6% of their amino acid sequences (using the
alignment programClustalO39). Shown are the functional domains and depiction of variants. Missense variants are colored in black, other variants are shown
in gray. The boxed variants represent developmental and epileptic encephalopathies. (B) Pedigrees of sporadic patients/families with newly identified
variants. F21 was adopted and there was no information about the biological parents. Abs = absence seizure; AS = atonic seizure; atyp. = atypical; CPS =
complex partial seizure; FE = focal epilepsy; FIAS = focal impaired awareness seizure; GEFS+ = genetic epilepsies with febrile seizures plus; GGE = genetic
generalized epilepsy; GTCS = generalized tonic-clonic seizure; IS = infantile spasms; Myo = generalizedmyoclonic seizure; TMR = transmembrane region; TS =
tonic seizure.
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genes in the human Syntaxin gene family. Disease variants are
enriched in paralog-conserved residues.21 In our paralog anal-
ysis, the SNARE motif turned out to be the most paralog-
conserved and gnomAD variant–depleted region of the protein
with the highest para_zscores (figure 3, A and B). Furthermore,
in a direct comparison of patient and gnomADmissense variant
distribution across the linear protein sequence, we observed
a significant enrichment of patient variants in the SNAREmotif
(p = 0.036). We ascertained missense variants in an unbiased
manner so that SNARE motif enrichment by chance is im-
probable. The amino acid positions of most of the detected
missense variants showed high or intermediate para_zscores.
There was no significant difference between the para_zscores
from missense variant positions in patients compared to those
in gnomAD (figure 3C). We also detected a few disease-
associated variants in regions with a high mutational density in
gnomAD and low para_zscores (p.Arg261Gln, p.Ile282Thr),
which were located in the transmembrane domain or the part
linking the SNARE motif with the transmembrane domain of
the protein.
Segregation of variants in families and
family histories
The segregation status for all variants in the respective pedi-
grees, together with a classification of the phenotypes, is
shown in figure 1B. Previously published pedigrees can be
found in Schubert et al.12 We validated inheritance in 6 of the
total 23 variants in families with more than one affected (4
new and 2 published). They were mostly cosegregating with
their phenotypes but also included both asymptomatic variant
carriers and phenocopies (F1, 2, 8, 13, 16, 20). In 3 patients,
a positive family history of epilepsy was available, but addi-
tional family members were not available for genetic testing
(F4, 11, 23). The available phenotypes of the other affected
individuals are depicted in figure 1B.
We showed de novo occurrence for 8 of the remaining 14 var-
iants, which were all detected in sporadic patients (F3, 5, 6, 7, 14,
17, 18, 19), whereas in 6 patients, the respective family members
were not available for segregation analysis (F9, 10, 12, 15, 21, 22).
Discussion
The current study expands the number of reported patients
with STX1B-related epileptic syndromes and describes 17 new
variants. Four different phenotypes can be discerned: (1)
a benign epilepsy syndrome with febrile and afebrile seizures
corresponding to GEFS+, (2) a GGE phenotype, (3) a DEE
syndrome with refractory seizures and moderate to severe
developmental deficits, and (4) a focal epilepsy phenotype.
STX1B-related epilepsies thus show a remarkable phenotypic
heterogeneity that is in its extent reminiscent of other epilepsy-
related genes, such as SCN1A,11 SCN2A,25 KCNQ2,26 and
STXBP1.27 In comparison to STXBP1, which is closely related
to STX1B (since the respective proteins interact with each
other in the synaptic transmitter release machinery) and
exhibits in most cases an early onset of epilepsy presenting as
Ohtahara syndrome or West syndrome,28 STX1B-related DEE
shows a later onset of epilepsy after the first birthday. Excep-
tions to this rule are F19 (p.A246P) and F21 (p.Q128Gfs*2)
who presented with a seizure onset within the first days of life
and are more reminiscent of STXBP1-related syndromes. It is
of interest that STX1B- and STXBP1-relatedDEEs both feature
ataxia and other movement disorders.28 However, in the vast
majority of STXBP1-related epilepsy syndromes, moderate to
Table 2 Prediction scores and para_zscore of newly identified missense variants
GRCh37/
hg19
position
Alternate
allele
CDS
position
Protein
position
Amino
acids SIFT PolyPhen-2
Mutation
Taster
para_
zscore
16:31004164 G 845 282 I/T Deleterious
(0.01)
Benign (0.104) D (1.0) −2.02
16:31004455 T 782 261 R/Q Deleterious
(0.01)
Probably damaging
(0.981)
D (1.0) −0.38
16:31004464 T 773 258 S/N Tolerated (0.06) Possibly damaging (0.491) D (1.0) −0.71
16:31004501 G 736 246 A/P Deleterious (0) Possibly damaging (0.919) D (1.0) 0.28
16:31004681 G 662 221 L/P Deleterious (0) Probably damaging (1) D (1.0) −0.71
16:31004715 T 628 210 E/K Deleterious (0) Probably damaging
(0.987)
D (1.0) 0.94
16:31008304 A 431 144 C/F Deleterious (0) Probably damaging
(0.998)
D (1.0) 0.28
16:31012267 A 262 88 V/F Deleterious
(0.01)
Probably damaging
(0.913)
D (1.0) 0.94
Abbreviations: PolyPhen-2 = polymorphism phenotyping v2; SIFT = sorting tolerant from intolerant.
Reported missense variants with in silico prediction scores. The table shows the genomic location of the variants in ascending order, the amino acid change,
and the predicted effect of these variants to the protein function by using SIFT, PolyPhen-2, andMutationTaster as well as the paralog conservation score. The
Genome Aggregation Database was used as a source for minor allele frequencies.
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severe developmental delay is present27–29—milder pheno-
types, as in our cohort, are not observed. In comparison to
other common DEE disorders, the median time of seizure
onset differentiates: neonatal or early infantile for SCN2A and
KCNQ2 (a later onset with these genes is rarer and associated
with different functional consequences—gain- vs loss-of-
function mutations25,26,30) and later infantile for SCN1A and
STX1B. Also in other aspects, parallels can be drawn with
SCN1A-related disorders. Thus, in 5 STX1B-related DEE cases,
FS and the presence of myoclonic seizures were reminiscent of
Dravet syndrome.31 However, the presence of tonic seizures in
these patients would be unusual forDravet syndrome. A patient
with generalized tonic-clonic, atonic, and myoclonic seizures
with onset at 1 year and severe developmental delay was
reported before this study with a 1.2 Mb de novo 16p11.2
deletion,13 including the STX1B gene. The phenotype was
classified as epilepsy with myoclonic-atonic seizures, a syn-
drome that has been associated with SCN1A in several
patients.32 The previously reported patient showed a remark-
able resemblance to F6 and F20, who also harbor a comparable
deletion. Another similarity with SCN1A is that our cohort
features several patients and families with GEFS+ syndrome7
and one patient with mesial temporal lobe epilepsy and FS (for
which common polymorphisms in SCN1A have been described
Figure 2 Mutational density and paralog conservation scores of STX1B missense variants
(A) Putative domain structure of syntaxin-1B (figure 1A). (B) Variation density in STX1B amino acid positions according to the Genome Aggregation Database
(gnomAD) depicting the reported missense variants. (C) Paralog conservation score (para_zscore) of the STX1B amino acid positions depicting the reported
missense variants (positive values are considered as paralog conserved). Previously reported variants12 are colored in gray, new variants in black. TMR =
transmembrane region.
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as a genetic risk factor33), and at least one GEFS+ multiplex
family with mesial temporal lobe epilepsy has been reported.34
Of interest is our patient with episodes reminiscent of hemi-
plegic migraine; SCN1A mutations are a recognized cause of
familial hemiplegic migraine.35 We acknowledge that the as-
sociation with a migraine-like syndrome in a single patient
could also be coincidental. In contrast, classic GGE syndromes,
such as represented by the 2 patients with JME in our cohort,
are not typically described in patients with SCN1A mutations.
Of note, both patients with JME had an atypical response of
pharmacoresistant seizures. In the DEE group, 7 of 13 (F3, F5,
F6, F14, F17, F18, F19) variants were de novo. This supports
the likelihood of a causative role in the context of the observed
phenotypes. Three missense variants showed a high paralog
conservation (p.C144F, p.G226R, p.A246P), increasing the
probability of a functional role. An exception to this rule was
p.I282T (F14), a variant that was discovered using a gene
panel approach. Possibly, despite the de novo status of this
variant, another as yet unknown genetic alteration in a gene not
captured by the gene panel might be more relevant in this case.
Although variant p.V216E (F4) showed a slightly negative
paralog score, this variant lies in a highly conserved region. The
patient had a positive family history and previous functional
data, i.e., rescue experiments in STX1B knockdown zebra fish
larvae12 support the pathogenicity of this variant. In F13
(p.N189Afs*5), both affected siblings had a similar phenotype.
This suggests an inheritance from the mother, who has not
been tested, while the father was tested negative. Since the
mother and other maternal family members were reportedly
not affected, germline mosaicism could be possible. However,
other genetic causes cannot be entirely excluded because the
variant was found in a gene panel of 85 epilepsy genes. In F15
(p.S258N), the prediction tools suggest a benign variant. Since
no family members were tested and the paralog score was
rather low, the role of this variant has to be considered carefully.
However, the variant is located at the end of the SNAREmotif,
which supports a causative role. In F16 (p.L221P), the family
history suggests an inherited defect. The variant was identified
by exome sequencing and no other convincing variants were
found. The unaffected mother also carries the variant but other
affected family members were not available for testing. Pre-
diction tools indicate a deleterious variant and the variant is
located in themiddle of the SNAREmotif, although the paralog
score was rather low; a case of incomplete penetrance is
therefore possible or the variant could represent a predisposing
factor for epilepsy. In F20, the gene deletion was inherited from
the father, who had a milder phenotype, suggesting the pres-
ence of other genetic modifiers. In F21 (p.Q128Gfs*2), the
parents were not tested and the variant was identified in a gene
panel of 115 candidate genes, so that other genetic causes
cannot be excluded. In the GEFS+ group, in 3 of 6 cases (F1,
F2, F8), a positive family history with cosegregating genetic
findings support the causative role of the reported variants. F7
(p.S10Afs7) was confirmed to be de novo. For F9 (p.R245*)
and F10 (p.Y140*), the parents were not tested. Since all
Figure 3 Mutational density and paralog conservation
score of different gene regions
(A) Distribution of mutational density of 4 STX1B gene regions. The SNARE
motif shows the lowest mutational density, the transmembrane region
(TMR) the highest density. (B) Paralog conservation score (para_zscore)
distribution of 4 STX1B gene regions. The SNARE motif shows the highest
paralog conservations, the TMR the lowest conservation. (C) Comparison of
paralog conservation score for all GenomeAggregation Database (gnomAD)
variants and patient variants.
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variants in this group predict a complete loss of function, we
consider them as disease-causing and the mechanism for the
GEFS+ group seems to be clearly a haploinsufficiency. In the
GGE group, neither case had parents who were tested. F11
(p.E210K) has a positive family history that is suggestive of an
inherited disease. The causative role of this variant is under-
scored by the in silico findings that the variant is predicted
deleterious, lies in a region of very low mutational density, and
shows high paralog conservation. p.K93* (F12) leads to
a haploinsufficiency, in line with the variants causing GEFS+.
Furthermore, this variant was identified by whole-genome se-
quencing and no other convincing variants were found. Of in-
terest, in a recent genome-wide association study of common
epilepsies, a significant signal in the region of STX1B was
detected in the JME cohort.36 In the FE group, the role of
STX1B should be considered more carefully. In F22 (p.R261Q)
and F23 (p.V88F), parents were not tested. For p.R261Q, the
established prediction tools point toward a deleterious variant,
while the position shows medium mutational density and low
paralog conservation. However, whole-genome sequencing
showed no other likely pathogenic variants. For p.V88F, the
used prediction tools show a more coherent picture of a dele-
terious variant, the paralog score was high, and whole-exome
sequencing found no other convincing variants.
Regarding genotype-phenotype correlation, it is notable that
missense variants in the functionally relevant SNARE motif
were identified in 6 of 7 patients or families (86%) associated
with DEE. The seventh patient (p.E210K) had refractory
JME. In contrast, all but one of the GEFS+ patients or families
had truncating variants (5 of 6, 83%) predicting nonsense-
mediated decay and complete loss of function of one allele
indicating haploinsufficiency as the disease mechanism.
A possible explanation could be that missense variants in crucial
protein regions, such as the SNAREmotif, may lead to a deficient
gene product that interferes with protein-protein interactions and
normal presynaptic vesicle fusion (dominant-negative effect),
whereas missense variants in the first part of the gene may affect
assembly of syntaxin-1B proteins and therefore have similar
consequences as a truncation with nonsense-mediated decay.
The loss-of-function mechanisms could also be compensated—
at least in part—by syntaxin-1A and, thus, be less damaging.37
We demonstrate that STX1B variants are linked to 4 different
epilepsy phenotypes. De novo dominant mutagenesis is the eti-
ology of most DEEs, whereas the more common epilepsies are
likely complex genetic disorders. This work suggests a role for
ultrarare STX1B variants in the pathogenesis of a broad range of
both common and rare epilepsies. There are plausible explan-
ations for genotype-phenotype correlations, such that hap-
loinsufficiency causes rather benign phenotypes, whereas
missense variants in functionally critical regions cause more se-
vere phenotypes. Other, unknown factors, which may include
genetic modifier, individual genetic background, and epigenetic
effects, could also have an important role and explain phenotypic
heterogeneity, reduced penetrance, and variable phenotypes
among carriers of truncating mutations. Functional studies on
a protein and cellular neuronal level will shed more light on the
relevance and degree of severity of the described variants and
contribute to a better understanding of the dysfunction of
syntaxin-1B and synaptic transmission in epilepsy and strengthen
our current interpretation of genotype-phenotype correlations.
Author contributions
S. Wolking: study concept and design, phenotyping and acqui-
sition of data, analysis and interpretation, writing of the manu-
script. P. May: analysis and interpretation, writing of the
manuscript. D. Mei: genotyping and acquisition of data. R.S.
Møller: phenotyping and acquisition of data, critical revision of
the manuscript for important intellectual content. S. Balestrini:
phenotyping and acquisition of data. K.L. Helbig: acquisition of
data. C. Desmettre Altuzarra: phenotyping and acquisition
of data. N. Chatron: phenotyping and acquisition of data.
C. Kaiwar: phenotyping and acquisition of data. K. Sto¨hr: phe-
notyping and acquisition of data. P. Widdess-Walsh: pheno-
typing and acquisition of data. B.A. Mendelsohn: phenotyping
and acquisition of data. A. Numis: phenotyping and acquisition
of data. M.R. Cilio: phenotyping and acquisition of data. W. Van
Paesschen: phenotyping and acquisition of data. L.L. Svendsen:
phenotyping and acquisition of data. S. Oates: phenotyping and
acquisition of data. E. Hughes: phenotyping and acquisition of
data. S. Goyal: phenotyping and acquisition of data. K. Brown:
acquisition of data. M. Sifuentes Saenz: phenotyping and ac-
quisition of data. T. Dorn: phenotyping and acquisition of data.
H. Muhle: phenotyping and acquisition of data. A.T. Pagna-
menta: acquisition of data, critical revision of the manuscript for
important intellectual content. D.V. Vavoulis: acquisition of data.
S.J.L. Knight: acquisition of data, critical revision of the manu-
script for important intellectual content. J.C. Taylor: acquisition
of data, critical revision of the manuscript for important in-
tellectual content. M.P. Canevini: phenotyping and acquisition
of data. F. Darra: phenotyping and acquisition of data. R.H.
Gavrilova: phenotyping and acquisition of data. Z. Powis: ac-
quisition of data. S. Tang: acquisition of data. J. Marquetand:
phenotyping and acquisition of data. M. Armstrong: acquisition
of data. D. McHale: acquisition of data. E.W. Klee: phenotyping
and acquisition of data, critical revision of the manuscript for
important intellectual content. G.J. Kluger: phenotyping and
acquisition of data, critical revision of the manuscript for im-
portant intellectual content. D.H. Lowenstein: phenotyping and
acquisition of data, critical revision of the manuscript for im-
portant intellectual content. S. Weckhuysen: phenotyping and
acquisition of data, critical revision of the manuscript for im-
portant intellectual content. D.K. Pal: phenotyping and acqui-
sition of data, critical revision of the manuscript for important
intellectual content. I. Helbig: phenotyping and acquisition of
data, critical revision of the manuscript for important intellectual
content. R. Guerrini: phenotyping and acquisition of data, critical
revision of the manuscript for important intellectual content,
analysis and interpretation. R.H. Thomas: phenotyping and
acquisition of data, critical revision of the manuscript for im-
portant intellectual content, analysis and interpretation. M.I.
Rees: phenotyping and acquisition of data, critical revision of the
10 Neurology | Volume 92, Number 11 | March 12, 2019 Neurology.org/N
manuscript for important intellectual content, analysis and in-
terpretation. G. Lesca: phenotyping and acquisition of data,
critical revision of the manuscript for important intellectual
content. S.M. Sisodiya: phenotyping and acquisition of data,
critical revision of the manuscript for important intellectual
content, analysis and interpretation. Y.G. Weber: phenotyping
and acquisition of data, critical revision of the manuscript
for important intellectual content. D. Lal: analysis and in-
terpretation, writing the manuscript. C. Marini: phenotyping
and acquisition of data, critical revision of the manuscript for
important intellectual content, analysis and interpretation.
H. Lerche: study concept and design, analysis and interpretation,
writing of the manuscript, study supervision. J. Schubert: study
concept and design, analysis and interpretation, writing of the
manuscript, study supervision
Acknowledgment
The authors thank the families and the study participants for
their permission to undertake the research, and the Epi4K
Consortium for contributing genetic data of one of the cases
from Allen et al. 201338 and the EuroEPINOMICS-RESMAE
Working Group for contributing one of the cases.
Study funding
This work was supported by the German Research Foundation
(DFG, grants Le1030/16-1, We4896/4-1, He5415/7-1, and
Kr5093/2-1), by the German Federal Ministry of Education and
Research (BMBF, in the frame of the ERA-NET NEURON
program, project SNAREopathies, grant 01EW1809A), and
by the Medical Faculty of the University of Tu¨bingen via the
Clinician Scientist Program (418-0-0) and the Fortu¨ne Pro-
gram (2306-0-0). This work was also supported by the
foundation “no epilep,” by the National Institute for Health
Research (NIHR) Biomedical Research Centre Oxford with
funding from the Department of Health’s NIHR Biomedical
Research Centre’s funding scheme; Epilepsy Research UK,
project grant P1104. Part of this work was undertaken at
University College London Hospitals, which received a pro-
portion of funding from the NIHR Biomedical Research
Centre funding scheme. The work was also supported by
a Wellcome Trust Strategic Award (WT104033AIA), the
Muir Maxwell Trust, and the Epilepsy Society, UK. The work
was also supported by the National Institute of Neurological
Disorders and Stroke (The Epilepsy Phenome/Genome
Project NS053998; Epi4KNS077364, NS077274, NS077303,
and NS077276). This work was also supported by grants from
the Canadian Institutes of Health Research (201503MOP-
342469, D.K.P.); European Union Program of the Seventh
Framework Program Development of Strategies for In-
novative Research to improve diagnosis, prevention, and
treatment in children with difficult to treat epilepsy, “DE-
SIRE” (EU grant agreement FP7 602531); NIH Research
(D.KP.); Medical Research Council (D.K.P.); Waterloo
Foundation (D.K.P.); Charles Sykes Epilepsy Research Trust
(D.K.P.); NIHR Specialist Biomedical Research Centre for
Mental Health of South London and Maudsley NHS Foun-
dation Trust (D.K.P.).
Disclosure
The authors report no disclosures relevant to the manuscript.
Go to Neurology.org/N for full disclosures.
Publication history
Received by Neurology April 5, 2018. Accepted in final form November
4, 2018.
References
1. Cossette P, Liu L, Brisebois K, et al. Mutation of GABRA1 in an autosomal dominant
form of juvenile myoclonic epilepsy. Nat Genet 2002;31:184–189.
2. Striano P, Weber YG, Toliat MR, et al. GLUT1 mutations are a rare cause of familial
idiopathic generalized epilepsy. Neurology 2012;78:557–562.
3. Chen Y, Lu J, Pan H, et al. Association between genetic variation of CACNA1H and
childhood absence epilepsy. Ann Neurol 2003;54:239–243.
4. Helbig I, Mefford HC, Sharp AJ, et al. 15q13.3 microdeletions increase risk of idio-
pathic generalized epilepsy. Nat Genet 2009;41:160–162.
5. Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus: a genetic
disorder with heterogeneous clinical phenotypes. Brain 1997;120:479–490.
6. Singh R, Scheffer IE, Crossland K, Berkovic SF. Generalized epilepsy with febrile
seizures plus: a common childhood-onset genetic epilepsy syndrome. Ann Neurol
1999;45:75–81.
7. Escayg A,MacDonald BT,MeislerMH, et al. Mutations of SCN1A, encoding a neuronal
sodium channel, in two families with GEFS+2. Nat Genet 2000;24:343–345.
8. Wallace RH, Scheffer IE, Parasivam G, et al. Generalized epilepsy with febrile seizures
plus: mutation of the sodium channel subunit SCN1B. Neurology 2002;58:
1426–1429.
9. Wallace RH, Marini C, Petrou S, et al. Mutant GABA(A) receptor gamma2-subunit in
childhood absence epilepsy and febrile seizures. Nat Genet 2001;28:49–52.
10. Dibbens LM, Feng HJ, Richards MC, et al. GABRD encoding a protein for extra- or
peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies.
Hum Mol Genet 2004;13:1315–1319.
11. Zuberi SM, Brunklaus A, Birch R, Reavey E, Duncan J, Forbes GH. Genotype-
phenotype associations in SCN1A-related epilepsies. Neurology 2011;76:594–600.
12. Schubert J, Siekierska A, Langlois M, et al. Mutations in STX1B, encoding a pre-
synaptic protein, cause fever-associated epilepsy syndromes. Nat Genet 2014;46:
1327–1332.
13. Vlaskamp DRM, Rump P, Callenbach PMC, et al. Haploinsufficiency of the STX1B
gene is associated with myoclonic astatic epilepsy. Eur J Paediatr Neurol 2016;20:
489–492.
14. Smirnova T, Miniou P, Viegas-Pequignot E, Mallet J. Assignment of the human
syntaxin 1B gene (STX) to chromosome 16p11.2 by fluorescence in situ hybridiza-
tion. Genomics 1996;36:551–553.
15. Lerche H, Weber YG, Baier H, et al. Generalized epilepsy with febrile seizures plus:
further heterogeneity in a large family. Neurology 2001;57:1191–1198.
16. Weber YG, Jacob M, Weber G, Lerche H. A BFIS-like syndrome with late onset and
febrile seizures: suggestive linkage to chromosome 16p11.2–16q12.1. Epilepsia 2008;
49:1959–1964.
17. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants
on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073–1081.
18. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting dam-
aging missense mutations. Nat Methods 2010;7:248–249.
19. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation pre-
diction for the deep-sequencing age. Nat Methods 2014;11:361–362.
20. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation
in 60,706 humans. Nature 2016;536:285–291.
21. Lal D,May P, Samocha K, et al. Gene family information facilitates variant interpretation
and identification of disease-associated genes. bioRxiv [online serial] Epub 2017 Jan 1.
Available at: biorxiv.org/content/early/2017/07/05/159780.abstract.
22. Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview version 2:
a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009;
25:1189–1191.
23. Khvotchev M, Dulubova I, Sun J, Dai H, Rizo J, Su¨dhof TC. Dual modes of Munc18-
1/SNARE interactions are coupled by functionally critical binding to syntaxin-1 N
terminus. J Neurosci 2007;27:12147–12155.
24. Gerber SH, Rah JC, Min SW, et al. Conformational switch of syntaxin-1 controls
synaptic vesicle fusion. Science 2008;321:1507–1510.
25. WolffM, Johannesen KM, Hedrich UBS, et al. Genetic and phenotypic heterogeneity
suggest therapeutic implications in SCN2A-related disorders. Brain 2017;140:
1316–1336.
26. Weckhuysen S, Ivanovic V, Hendrickx R, et al. Extending the KCNQ2 encephalop-
athy spectrum: clinical and neuroimaging findings in 17 patients. Neurology 2013;81:
1697–1703.
27. Carvill GL, Weckhuysen S, McMahon JM, et al. GABRA1 and STXBP1: novel genetic
causes of Dravet syndrome. Neurology 2014;82:1245–1253.
28. Di Meglio C, Lesca G, Villeneuve N, et al. Epileptic patients with de novo STXBP1
mutations: key clinical features based on 24 cases. Epilepsia 2015;56:1931–1940.
29. Saitsu H, Kato M, Mizuguchi T, et al. De novo mutations in the gene encoding
STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet
2008;40:782–788.
Neurology.org/N Neurology | Volume 92, Number 11 | March 12, 2019 11
30. Miceli F, Soldovieri MV, Ambrosino P, et al. Early-onset epileptic encephalopathy
caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 po-
tassium channel subunits. J Neurosci 2015;35:3782–3793.
31. Dravet C, Guerrini R. Dravet Syndrome. Montrouge: John Libbey Eurotext; 2011.
32. Tang S, Pal DK. Dissecting the genetic basis of myoclonic-astatic epilepsy. Epilepsia
2012;53:1303–1313.
33. Kasperavicˇiute˙ D, Catarino CB, Matarin M, et al. Epilepsy, hippocampal sclerosis and
febrile seizures linked by common genetic variation around SCN1A. Brain 2013;136:
3140–3150.
34. Abou-Khalil B, Ge Q, Desai R, et al. Partial and generalized epilepsy with febrile
seizures plus and a novel SCN1A mutation. Neurology 2001;57:2265–2272.
35. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated
sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005;366:371–377.
36. The International League Against Epilepsy Consortium on Complex Epilepsies.
Genome-wide mega-analysis identifies 16 loci and highlights diverse biological
mechanisms in the common epilepsies. Nat Commun 2018;9:5269.
37. Zhou P, Pang ZP, Yang X, et al. Syntaxin-1 N-peptide and Habc-domain perform
distinct essential functions in synaptic vesicle fusion. EMBO J 2013;32:159–171.
38. Allen AS, Berkovic SF, Cossette P, et al. De novo mutations in epileptic encephalo-
pathies. Nature 2013;501:217–221.
39. McWilliam H, Li W, Uludag M, et al. Analysis Tool Web Services from the EMBL-
EBI. Nucleic Acids Res 2013;41:W597–W600.
12 Neurology | Volume 92, Number 11 | March 12, 2019 Neurology.org/N
DOI 10.1212/WNL.0000000000007089
 published online February 8, 2019Neurology 
Stefan Wolking, Patrick May, Davide Mei, et al. 
-related epileptic disordersSTX1BClinical spectrum of 
This information is current as of February 8, 2019
Services
Updated Information &
 089.full
http://n.neurology.org/content/early/2019/02/08/WNL.0000000000007
including high resolution figures, can be found at:
Subspecialty Collections
 http://n.neurology.org/cgi/collection/all_genetics
All Genetics
 http://n.neurology.org/cgi/collection/all_epilepsy_seizures
All Epilepsy/Seizures
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://www.neurology.org/about/about_the_journal#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://n.neurology.org/subscribers/advertise
Information about ordering reprints can be found online:
ISSN: 0028-3878. Online ISSN: 1526-632X.
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Print
1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2019 The Author(s). Published by 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
